Ligand News and Research

RSS

Zinc deficiency can activate Hedgehog signaling pathway

Zinc deficiency - long associated with numerous diseases, e.g. autism, lung cancer, prostate cancer, and ovarian cancers - can lead to activation of the Hedgehog signaling pathway, a biomolecular pathway that plays essential roles in developing organisms and in diseases, according to new research at Rensselaer Polytechnic Institute.

17 Apr 2015

USPTO issues Cardio3 BioSciences Notice of Allowance for patent covering CAR-expressing TCR-deficient T-Cells

Cardio3 BioSciences, a leader in engineered cell therapies with clinical programs initially targeting indications in cardiovascular disease and oncology, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a significant patent application covering T-Cell receptor-deficient T-Cells which are engineered to express a chimeric antigen receptor.

9 Apr 2015

Peripheral inflammatory cells play role in Parkinson's disease

A small area in the midbrain known as the substantia nigra is the control center for all bodily movement. Increasing loss of dopamine-generating neurons in this part of the brain therefore leads to the main symptoms of Parkinson's disease - slowness of movement, rigidity and shaking.

3 Apr 2015

Radiation resistance in leukemia can be overcome by using new precision medicine, say researchers

A team of researchers led by Fatih M. Uckun, MD, PhD, of The Saban Research Institute of Children's Hospital Los Angeles and Professor at the University of Southern California Keck School of Medicine has determined that radiation resistance in leukemia can be overcome by using an engineered protein they recently designed and developed as a new precision medicine against leukemia.

27 Mar 2015

Philip Low to be recognized with AACR Award for Outstanding Achievement in Chemistry in Cancer Research

The American Association for Cancer Research will recognize Philip S. Low, PhD, with the ninth annual AACR Award for Outstanding Achievement in Chemistry in Cancer Research at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22.

26 Mar 2015

Rigontec raises €4.8 million in second closing of Series A financing round

Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, today announces it has raised €4.8 million in a second closing of its Series A financing round from Forbion Capital Partners, a Dutch life-sciences venture capital firm, and Sunstone Capital, a Copenhagen based venture capital investor.

24 Mar 2015

BAI researchers develop new brain image analysis method to better track amyloid changes

Researchers from Banner Alzheimer's Institute have developed a new brain image analysis method to better track the progression of beta-amyloid plaque deposition, a characteristic brain abnormality in Alzheimer's disease, according to a study published in the March issue of the Journal of Nuclear Medicine.

20 Mar 2015

New immunotoxin found to be safe, effective in patients with B-cell malignancies

Almost all patients with a group of blood cancers called B-cell malignancies have two prominent "fingerprints" on the surface of leukemia and lymphoma cancers, called CD22 and CD19, Vallera explained.

13 Mar 2015

TSRI chemists develop innovative method for building new drug molecules

Chemists at The Scripps Research Institute have developed a broadly useful technique for building new drug molecules and other chemical products.

12 Mar 2015

Andor Neo sCMOS camera is perfect partner for correlative microscopy

CD44 is recognised as an important cell surface receptor involved in the adhesion of circulating leukocytes to endothelium, a process that is critical for their trafficking in the vasculature. Now, a Japanese group of researchers using an ultra-sensitive Andor Neo sCMOS camera in their correlative microscopy set-up has demonstrated that microvilli projections around the cell surface mediate this adhesion.

From Andor Technology Ltd. 11 Mar 2015

Advanced Cell Diagnostics' RNAscope technology supports biomarker-selected phase 2 clinical trial of Merrimack Pharmaceuticals' MM-121

Advanced Cell Diagnostics, Inc. (ACD) announced today that Merrimack Pharmaceuticals, Inc. is using ACD's RNAscope technology to select patients for its Phase 2 clinical trial of its product candidate MM-121.

From Advanced Cell Diagnostics 9 Mar 2015

Androgen receptor in prostate cancer cells can activate different gene set when bound to antiandrogens

The androgen receptor in prostate cancer cells can activate different sets of genes depending on whether it binds with an androgen hormone or an antiandrogen drug, according to a new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

28 Jan 2015

CHLA researchers develop new protein-based therapy against drug-resistant leukemia cells

Resistance of leukemia cells to contemporary chemotherapy is one of the most formidable obstacles to treating acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Now researchers at Children's Hospital Los Angeles have designed and developed a new protein-based therapy they believe will prove highly effective against drug-resistant leukemia cells.

27 Jan 2015

Researchers decode how cancer uses cell-cell interaction mechanism to promote metastasis

Cancer uses a little-understood element of cell signaling to hijack the communication process and spread, according to Rice University researchers.

27 Jan 2015

NCCS launches human clinical trial of new cancer vaccine

The National Cancer Centre Singapore has launched a clinical trial of a new cancer vaccine administered to human patients for the first time in the world. Cancer immunotherapy (the harnessing of the body's defence system to fight the patient's cancer, has emerged as one of the most exciting medical breakthroughs in the past two years.

22 Jan 2015

Heptares Therapeutics, AstraZeneca report significant progress in drug discovery collaboration

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, announces significant progress in its drug discovery collaboration with AstraZeneca.

22 Jan 2015

Modelling the biological mesoscale: an interview with Professor Art Olson

The biological mesoscale range includes biological structures that range from 10 to 100 nanometers (billionths of a meter). Structures in this size range include viruses, cellular organelles, large molecular complexes, and any other internal cellular environments within that range.

18 Jan 2015

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody ("mAb") targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea.

14 Jan 2015

UT Southwestern researchers identify cell signaling mechanism that plays vital role in brain cancer

UT Southwestern Medical Center neurology researchers have identified an important cell signaling mechanism that plays an important role in brain cancer and may provide a new therapeutic target.

16 Dec 2014

PD-L1 expression tied to favourable prognosis in SCLC

Programmed death-ligand 1 is expressed by around 70% of small-cell lung cancers and is associated with favourable patient outcomes, Japanese researchers report.

10 Dec 2014